|hCD80-Fc||Unit size||Cat. code||Docs||Qty||Price|
Soluble human CD80 fused to an IgG1 Fc domain
hCD80-Fc is a soluble human CD80 fusion protein generated by fusing the N-terminal extracellular domain of human CD80 (aa 35-238) to the N-terminus of an engineered human IgG1 Fc domain with a 2 amino acid linker.
hCD80-Fc has an apparent molecular weight of ~68 kDa on SDS‑PAGE.
hCD80-Fc is expressed in CHO cells and purified by protein G affinity chromatography.
Applications: Flow cytometry, protein-protein binding assays, T cells activation (hCD28 binding), Treg cellular activity blocking (hCTLA4 binding).
Formulation: 0.2 µm filtered solution in sodium phosphate buffer with glycine, saccharose and stabilizing agentsBack to the top
- 50 µg lyophilized hCD80-Fc.
- 1.5 ml endotoxin-free water.
Product is shipped at room temperature.
Store lyophilized product at -20°C.
Product is stable for at least 1 year.Back to the top
Custer of differentiation 80 (CD80), also known as B7-1, is a member of the B7 family of immunoregulatory proteins. It is expressed on antigen‑presenting cells (APCs) and is essential for T cell activation.
It binds the T cell critical costimulatory molecule CD28 and the inhibitory receptor CTLA-4 (also known as CD152).
Binding of CD80 to CD28 evokes a costimulatory signal essential for T-lymphocyte activation, T-cell proliferation and cytokine production whilst binding to CTLA‑4 has the opposite effect and inhibits T-cell activation.
Collins M. et al., 2005. The B7 family of immune-regulatory ligands. Genome Biol. 6(6):223.
Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.